DRAXIS Names New President and Chief Executive Officer as well as New Chief Operating Officer



    MONTREAL, Jan. 8 /CNW/ - The Board of Directors of DRAXIS Health Inc.
(TSX: DAX) (NASDAQ:   DRAX) has appointed Mr. Dan Brazier as the new President
and Chief Executive Officer effective January 1, 2008. In addition, the Board
has also appointed Mr. Jean-Pierre Robert to the position of Chief Operating
Officer of DRAXIS Health Inc.
    Brian King, Chair of the Board of Directors, said, "The Board of
Directors has full confidence that the streamlined executive management team
under Dan Brazier's leadership has the capabilities to deliver on its
strategic plan for the Company that positions DRAXIS for significant growth
beginning in 2008 and extending into the future. Recently announced
partnerships, new business activities and the continuing development of
several significant new products that are expected to be introduced over the
next several years represent significant opportunities for value creation."
    Mr. Jean-Pierre Robert will also continue to retain his position as
President of DRAXIS Specialty Pharmaceuticals Inc. (DSP), the Company's
wholly-owned operating subsidiary. These new appointments are the result of a
long term process established by the Company to identify a successor to Dr.
Martin Barkin who recently informed the Board of his decision to retire as
President and CEO and resign from the Board of Directors, both effective
December 31, 2007.

    About Dan Brazier

    Dan Brazier has been a member of the executive management team since he
joined DRAXIS in 1998. He was named Chief Operating Officer in October 2005
and since July 2007 he served in the Office of the President together with Dr.
Barkin. Prior to his appointment as COO Mr. Brazier was Senior Vice President,
Corporate Development and Strategic Planning since June 2003. Previously, he
served as the President of the Canadian pharmaceutical sales and marketing
division of DRAXIS Health, where he successfully transformed and grew the
division from a relatively small unit that marketed several unrelated product
lines into a profitable specialty pharmaceuticals business with a well-defined
focus in prescription products for the neurology segment.
    Mr. Brazier has nearly 30 years of business experience with several
consumer marketing, healthcare and pharmaceutical companies in a variety of
increasingly responsible roles that included responsibilities in Canada, the
United States and internationally. He has held a variety of senior positions
including sales and marketing management, general management, strategic
planning, corporate development and executive management roles. Prior to
joining DRAXIS Health he established a specialty products division within a
major international pharmaceutical company and led that division through a
period of rapid growth. Mr. Brazier holds an honours degree in Commerce, with
a double major in both Marketing and Finance.

    About Jean-Pierre Robert

    Jean-Pierre Robert joined DRAXIS in April 2005 as President of the
radiopharmaceuticals business unit in Montreal and as a member of the
executive management team. In July 2007 he assumed the role of President of
DRAXIS Specialty Pharmaceuticals Inc. In that position he has responsibility
for both DRAXIMAGE, the division of DSP that produces and markets its own
radiopharmaceutical products and for DRAXIS Pharma, the contract manufacturing
division of DSP, which produces sterile and non-sterile products for clients
in the pharmaceutical and biotechnology sectors.
    Before joining DRAXIS, Mr. Robert spent several years with Tyco
Healthcare (Canada), now Covidien Ltd., most recently as Vice President and
General Manager, an executive role where he oversaw domestic and export
operations including marketing, sales, finance, and contract manufacturing
operations. Immediately prior to joining DRAXIS Mr. Robert was President and
CEO of an emerging Canadian biopharmaceutical company. Mr. Robert has 28 years
experience in the pharmaceutical industry and holds a B.Sc. degree.

    About DRAXIS Health Inc.:

    DRAXIS Health, through its wholly owned operating subsidiary, DRAXIS
Specialty Pharmaceuticals Inc., provides products in three categories: sterile
products, non-sterile products and radiopharmaceuticals. Sterile products
include liquid and freeze-dried (lyophilized) injectables plus sterile
ointments and creams. Non-sterile products are produced as solid oral and
semi-solid dosage forms. Radiopharmaceuticals are used for both therapeutic
and diagnostic molecular imaging applications. Pharmaceutical contract
manufacturing services are provided through the DRAXIS Pharma division and
radiopharmaceuticals are developed, produced, and sold through the DRAXIMAGE
division. DRAXIS employs approximately 500 staff in its Montreal facility.
    For additional information please visit www.draxis.com

    Caution Concerning Forward-Looking Statements

    This news release contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended (the "Securities
Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act") and as contemplated under other applicable securities
legislation. These statements can be identified by the use of forward-looking
terminology such as "may," "will," "expect," "anticipate," "estimate,"
"continue," "plan," "intend," "believe" or other similar words. These
statements discuss future expectations concerning results of operations or
financial condition or provide other forward-looking information. Our actual
results, performance or achievements could be significantly different from the
results expressed in, or implied by, those forward-looking statements. You
should not place undue reliance on any forward-looking statement, which speaks
only as of the date made.
    These statements are not guarantees of future performance. By their
nature, forward-looking statements involve numerous assumptions, known and
unknown risks, uncertainties and other factors that may cause the actual
results or performance of the Company to be materially different from such
statements or from any future results or performance implied thereby. Factors
that could cause the Company's results or performance to differ materially
from a conclusion, forecast or projection in the forward-looking statements
include, but are not limited to:
    
    -  the achievement of desired clinical trial results related to the
       Company's pipeline products;
    -  timely regulatory approval of the Company's products;
    -  the ability to comply with regulatory requirements applicable to the
       manufacture and marketing of the Company's products;
    -  the Company's ability to obtain and enforce effective patents;
    -  the non-infringement of third party patents or proprietary rights by
       the Company and its products;
    -  factors beyond our control that could cause interruptions in our
       operations in our single manufacturing facility (including, without
       limitation, material equipment breakdowns);
    -  reimbursement policies related to health care;
    -  the establishment and maintenance of strategic collaborative and
       commercial relationships;
    -  the Company's dependence on a small number of key customers;
    -  the disclosure of confidential information by our collaborators,
       employees or consultants;
    -  the preservation of healthy working relationships with the Company's
       union and employees;
    -  the Company's ability to grow the business;
    -  the fluctuation of our financial results and exchange and interest
       rate fluctuations;
    -  the adaptation to changing technologies;
    -  the loss of key personnel;
    -  the avoidance of product liability claims;
    -  the loss incurred if current lawsuits against us succeed;
    -  the volatility of the price of our common shares;
    -  market acceptance of the Company's products;
    -  factors described under "Outlook" in the Company's MD&A for the most
       recent quarter; and
    -  the risks described in "Item 3. Key Information - Risk Factors" in the
       Annual Report Form 20-F filed by the Company with the United States
       Securities and Exchange Commission and which is also filed as the
       Company's Annual Information Form with Canadian securities regulators.
    

    For additional information with respect to certain of these and other
factors, and relating to the Company generally, reference is made to the
Company's most recent filings with the United States Securities and Exchange
Commission (available on EDGAR at www.sec.gov) and the filings made by the
Company with Canadian securities regulators (available on SEDAR at
www.sedar.com). The forward-looking statements contained in this document
represent the Company's expectations as at January 7, 2008. Unless otherwise
required by applicable securities laws, the Company disclaims any intention or
obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.

    %SEDAR: 00004049E




For further information:

For further information: DRAXIS Health Inc.: Jerry Ormiston, Executive
Director, Investor Relations, Phone: 1-877-441-1984

Organization Profile

DRAXIS SPECIALTY PHARMACEUTICALS INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890